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Abstract: The activation of human bronchial fibroblasts by transforming growth factor-β1
(TGF-β1) leads to the formation of highly contractile myofibroblasts in the process of the
fibroblast–myofibroblast transition (FMT). This process is crucial for subepithelial fibrosis and
bronchial wall remodeling in asthma. However, this process evades current therapeutic asthma
treatment strategies. Since our previous studies showed the attenuation of the TGF-β1-induced FMT
in response to lipid-lowering agents (e.g., statins), we were interested to see whether a corresponding
effect could be obtained upon administration of hypolipidemic agents. In this study, we investigated
the effect of fenofibrate on FMT efficiency in populations of bronchial fibroblasts derived from
asthmatic patients. Fenofibrate exerted a dose-dependent inhibitory effect on the FMT, even though it
did not efficiently affect the expression of α-smooth muscle actin (α-SMA; marker of myofibroblasts);
however, it considerably reduced its incorporation into stress fibers through connexin 43 regulation.
This effect was accompanied by disturbances in the actin cytoskeleton architecture, impairments in
the maturation of focal adhesions, and the fenofibrate-induced deactivation of TGF-β1/Smad2/3
signaling. These data suggest that fenofibrate interferes with myofibroblastic differentiation during
asthma-related subepithelial fibrosis. The data indicate the potential application of fenofibrate in the
therapy and prevention of bronchial remodeling during the asthmatic process.
Keywords: fibroblast-to-myofibroblast transition; TGF-β/Smad signaling; fenofibrate; bronchial
asthma; actin cytoskeleton architecture; connexin 43
1. Introduction
Contemporary views on asthma pathophysiology suggest that the asthmatic process in proximal
bronchi is associated with chronic inflammation-induced bronchial wall remodeling [1,2]. Bronchial
asthma is manifested by a wide range of histopathological changes in the bronchial wall. These changes
comprise epithelial dysfunction and an unbalanced increase in the airway smooth muscle mass and
subepithelial fibrosis, which is associated with the abnormal activation of bronchial fibroblasts [3].
Because of the bronchial wall remodeling, a functional impairment of asthmatic bronchi and chronic
airflow obstruction occurs. This impairment is accompanied by chronic inflammation that further
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promotes pro-fibrotic changes in the bronchial airway walls [4]. In particular, the asthmatic bronchi
microenvironment is rich in locally secreted pro-inflammatory cytokines and growth factors (especially
TGF-β1), which favor the myofibroblastic differentiation of bronchial fibroblasts.
The Global Strategy for Asthma Management and Prevention report clearly shows an increasing
number of bronchial asthma cases in the last several decades [5]. Therefore, new therapeutic strategies
that would help interrupt this vicious circle are necessary. Whereas inflammation remains the primary
target of asthma therapies [6,7], these therapies have a negligible effect on structure and hardly
attenuate the structural changes in asthmatic airways [8,9]. This problem underlies the need for
elaboration of new therapeutic approaches that directly target the pro-fibrotic processes, including the
fibroblast–myofibroblast transition (FMT).
It is generally accepted that the progression of subepithelial fibrosis in asthma is
predominantly determined by an increased myofibroblastic differentiation and increased longevity
of myofibroblasts, leading to their accumulation in bronchial walls [4,10]. Two basic features of
these cells, i.e., their contractility and pro-fibrotic activity, are determined by a well-developed
α-smooth-muscle-actin-positive (α-SMA+) contractile apparatus and secretion of extracellular matrix
(ECM) components, respectively [11,12]. These features are acquired in the FMT process in response to
mechanical and/or humoral stimuli, which concomitantly prompt the formation of α-smooth muscle
actin (α-SMA) microfilaments in phenotypically plastic fibroblasts [13,14]. Due to the crucial role
of the FMT in subepithelial fibrosis and the involvement of subepithelial fibrosis in the asthmatic
process, it is conceivable that pharmacologic attenuation of this process may constitute a milestone
in asthma treatment. An increasing amount of evidence shows that lipid metabolism disorders that
lead to obesity are significant risk factors that favor asthma progression [15,16]. Our previous study
indicated the impact of statins (lovastatin and squalestatin) on the progression of subepithelial fibrosis
during asthma, which was accomplished through the attenuation of phenotypic shifts of bronchial
fibroblasts into myofibroblasts [17]. These data attracted our attention for the potential application of
other anti-hyperlipidemic drugs in asthma treatment.
Numerous reports described an anti-inflammatory and anti-fibrotic potential of fenofibrate.
Fenofibrate is a Food and Drug Administration (FDA)-approved agent, routinely used in
hyperlipidemia treatment [18]. Studies performed with human, rat, and mouse models of lung
disorders, including asthma and idiopathic pulmonary fibrosis [19–22], suggest that fenofibrate
can be useful in the elaboration of pharmacotherapeutic approaches targeting fibrotic changes in
the subepithelial layer of asthmatic bronchi. However, the effect of fenofibrate on bronchial wall
remodeling and FMT efficiency in asthma is yet to be studied. To fill this gap, we estimated the effect
of fenofibrate on the TGF-β1-induced FMT in populations of bronchial fibroblasts. For this purpose,
we used an experimental model based on human bronchial fibroblasts propagated in vitro from the ex
vivo bronchial biopsies of patients with diagnosed asthma.
2. Results
2.1. Fenofibrate Attenuates the TGF-B1-Induced Differentiation of Human Bronchial Fibroblasts
into Myofibroblasts
Although fenofibrate is commonly used in the therapy of lipid metabolism disorders, it was also
reported that fenofibrate inhibits collagen production during lung fibrotic disease [22]. In asthmatic
bronchi, collagen is predominantly deposited by bronchial fibroblasts and myofibroblasts; therefore,
we estimated the effect of fenofibrate on myofibroblastic differentiation of HBFs derived from
asthmatics. Viability tests demonstrated the lack of any cytotoxic effects of fenofibrate on human
bronchial fibroblasts (HBFs) at concentrations up to 50 µM (Figure 1A).
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Figure 1. Fenofibrate does not affect the viability, proliferation, morphology, or motility of human 
bronchial fibroblasts (HBFs). (A) HBFs derived from asthma patients were cultured in the absence or 
presence of fenofibrate (FF; 1–50 μM) for one, two, and seven days, and the number of viable cells 
was detected using the fluorescein diacetate/ethidium bromide (FDA/EtBr) test. (B) Proliferation of 
HBFs after FF (0–50 μM) administration was measured after one, three, five, and seven days of cell 
cultivation, presented as a mean value of crystal violet absorbance. (C) Representative images of HBF 
morphologies after treatment with FF for 48 h (integrated modulation contrast, IMC). Scale bar = 25 
μm. (D,E) HBFs were cultured in the absence or presence of FF (25 μM) for 48 h. The results of time-
lapse monitoring of HBF movement are presented as circular diagrams, with the starting point of each 
trajectory situated at the plot center and column charts summarizing the effect of FF on the average 
speed of cell movement (ASCM; μm/h) and the average rate of cell displacement (ARCD; μm) 
parameters. (F) Intracellular cholesterol levels of HBF populations (n = 10) were measured with an 
Amplex Cholesterol Assay Kit after seven days of FF treatment (10 or 25 μM) in three independent 
experiments and are shown on a graph. Data are the mean ± standard error of the mean (SEM) of six 
independent experiments. Statistical significances were tested using one-way (A,C,F) or two-way 
ANOVA (B) with the Bonferroni multiple comparison post hoc test; * p ≤ 0.05. 
Absence of the deleterious effects of fenofibrate on HBFs was further verified by proliferation 
tests (Figure 1B), followed by morphological analyses (Figure 1C) and time-lapse analyses of HBF 
motility (Figure 1D,E). These analyses did not reveal any significant effect of fenofibrate on these 
parameters. However, we observed hypolipemic effects manifested by the analyses of intracellular 
cholesterol levels, which were significantly reduced in HBFs exposed to 25 μM fenofibrate (Figure 
1F). 
Further analyses were performed to estimate the effect of fenofibrate on the TGF-β1-induced 
FMT in HBF populations (n = 10). For this purpose, fibroblasts were cultivated for seven days in the 
presence of fenofibrate (1–50 μM) and in the presence/absence of TGF-β1. In response to TGF-β1, HBFs 
efficiently differentiated into highly contractile myofibroblasts, characterized by abundant α-SMA+ 
stress fibers (up to ca. 60% of population; Figure 2A,B). 
Figure 1. Fenofibrate does not affect the viability, proliferation, morphology, or motility of human
bronchial fibroblasts (HBFs). (A) HBFs derived from asthma patients were cultured in the absence or
presence of fenofibrate (FF; 1–50 µM) for one, two, and seven days, and the number of viable cells
was detected using the fluorescein diacetate/ethidium bromide (FDA/EtBr) test. (B) Proliferation
of HBFs after FF (0–50 µM) administration was measured after one, three, five, and seven days of
cell cultivation, presented as a mean value of crystal violet absorbance. (C) Representative images of
HBF morphologies after treatment with FF for 48 h (integrated modulation contrast, IMC). Scale bar
= 25 µm. (D,E) HBFs were cultured in the absence or presence of FF (25 µM) for 48 h. The results of
time-lapse monitoring of HBF movement are presented as circular diagrams, with the starting point
of each trajectory situated at the plot center and column charts summarizing the effect of FF on the
average speed of cell movement (ASCM; µm/h) and the average rate of cell displacement (ARCD; µm)
parameters. (F) Intracellular cholesterol levels of HBF populations (n = 10) were measured with an
Amplex Cholesterol Assay Kit after seven days of FF treatment (10 or 25 µM) in three independent
experiments and are shown on a graph. Data are the mean ± standard error of the mean (SEM) of
six independent experiments. Statistical significances were tested using one-way (A,C,F) or two-way
ANOVA (B) with the Bonferroni multiple comparison post hoc test; * p ≤ 0.05.
Absence of the deleterious effects of fenofibrate on HBFs was further verified by proliferation tests
(Figure 1B), followed by morphological analyses (Figure 1C) and time-lapse analyses of HBF motility
(Figure 1D,E). These analyses did not reveal any significant effect of fenofibrate on these parameters.
However, we observed hypolipemic effects manifested by the analyses of intracellular cholesterol
levels, which were significantly reduced in HBFs exposed to 25 µM fenofibrate (Figure 1F).
Further analyses were performed to esti ate the effect of fenofibrate on the TGF-β -induced
FMT in HBF populations (n = 10). For this purpose, fibroblasts ere cultivated for seven days in the
presence of fenofibrate (1–50 µM) and in the presence/absence of TGF-β1. In response to T F-β , BFs
efficiently differentiated into highly contractile myofibroblasts, c aracterize by ab a t -S +
stress fibers (up to ca. 60% of population; Figure 2A,B).
Fenofibrate reduced this effect in a dose-dependent manner. Interestingly, immunoblot analyses
did not reveal any significant impact of fenofibrate on α-SMA levels in the HBF populations (Figure 2C).
This somewhat unexpected observation prompted us to verify these data with in-cell ELISA (Figure 2D).
These immunoenzymatic studies showed a slight impact of fenofibrate onα-SMA levels, which was less
pronounced than the effect on FMT efficiency. Also, decreased content of fibronectin (another marker
of myofibroblasts) confirmed the attenuation of phenotypic shifts in TGF-β1/fenofibrate-treated HBFs.
These observations demonstrate that fenofibrate exerts an inhibitory effect on the TGF-β1-induced
FMT in HBF populations predominantly via inhibition of α-SMA incorporation into stress fibers.
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Figure 2. Fenofibrate attenuates the TGF-β1-induced phenotypic transition of HBFs into 
myofibroblasts. (A) HBFs were cultured in control conditions or in Dulbecco’s modified Eagle 
medium (DMEM) supplemented with TGF-β1 (5 ng/mL) in the absence or presence of FF (1–25 μM) 
for seven days. Then, the cells were fixed with 3.7% formaldehyde, permeabilized, and 
immunostained for α-smooth muscle actin (α-SMA; green) and DNA (blue) as shown on 
representative images. Scale bar = 25 μm. (B) The fraction of cells with prominent α-SMA+ stress fibers 
in HBF populations (n = 10) was determined using fluorescence microscopy in three independent 
experiments. (C) Analyses of α-SMA content were carried out in total cell lysates from HBFs cultured 
as in (A) using immunoblotting. Human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as a loading control. The effect of fenofibrate on the α-SMA levels in the TGF-β1-treated HBFs is 
presented as a bar graph and shows densitometric quantification of Western blots. Data are the mean 
± SEM of five independent experiments in triplicate. (D,E) α-SMA and fibronectin contents, 
respectively, were defined using in-cell ELISA, and the results are presented as the mean value of 
absorbance (450 nm) reflecting the protein content. Data represent the mean ± SEM carried out on 
HBFs (n = 10), each in triplicate. Statistical significances were tested using one-way ANOVA with the 
Bonferroni multiple comparison post hoc test; * p ≤ 0.05, *** p ≤ 0.001. Note that fenofibrate 
significantly inhibits the formation of α-SMA+ stress fibers in the TGF-β1-treated HBFs in a dose-
dependent manner, and concomitantly, has a slight impact on the total α-SMA level. 
Fenofibrate reduced this effect in a dose-dependent manner. Interestingly, immunoblot analyses 
did not reveal any significant impact of fenofibrate on α-SMA levels in the HBF populations (Figure 
2C). This somewhat unexpected observation prompted us to verify these data with in-cell ELISA 
(Figure 2D). These immunoenzymatic studies showed a slight impact of fenofibrate on α-SMA levels, 
which was less pronounced than the effect on FMT efficiency. Also, decreased content of fibronectin 
(another marker of myofibroblasts) confirmed the attenuation of phenotypic shifts in TGF-
β1/fenofibrate-treated HBFs. These observations demonstrate that fenofibrate exerts an inhibitory 
effect on the TGF-β1-induced FMT in HBF populations predominantly via inhibition of α-SMA 
incorporation into stress fibers. 
2.2. Actin Cytoskeleton Architecture Is Reorganized by Fenofibrate in TGF-β1-Treated HBFs 
To mechanically address the inhibition of α-SMA incorporation into stress fibers, we further 
concentrated on their actin cytoskeleton architecture in the fenofibrate-treated HBFs. Fenofibrate 
considerably reduced the thickness and affected cytoplasmic localization of stress fibers in the TGF-
β1-treated HBFs (Figure 3A). 
Figure 2. Fenofibrate attenuates the TGF-β1-induced phenotypic transition of HBFs into myofibroblasts.
(A) HBFs were cultured in control conditions or in Dulbecco’s modified Eagle medium (DMEM)
supple ented with TGF-β1 (5 ng/mL) in the absence or presence of FF (1–25 µM) for seven days.
Then, the cells were fixed with 3.7% formaldehy e, permeabilized, and immunostained for α-smooth
uscle acti (α-SMA; green) and DNA (blue) as shown on representative images. Scale bar =
25 µm. (B) The fraction of cells with prominent α-SMA+ stre s fibers in HBF populations (n = 10)
was determined using fluorescence microscopy i three independent experimen s. (C) Analyses of
α-SMA content were carried out in total cell lysates from HBFs cultured as in (A) using immunoblotting.
Human glyceraldehyde 3-phosphate dehydrog nase (GAPDH) was us d as a loading control. The effect
of fenofibrate on the α-SMA levels in the TGF-β1-treated HBFs is presented as a bar graph and
shows densitometric quantification of Western blots. Data re the mean ± SEM of five indep ndent
experiments n triplicat . (D,E) α-SMA and fibronectin contents, respectively, were defi d using in-cell
ELISA, and the results are presented as the mean value of absorbance (450 nm) reflecting the protein
content. Data represent the mean ± SEM carried out on HBFs (n = 10), each in triplicate. Statistical
significances were tested using one-way ANOVA with th Bonferroni multiple comparison post hoc
test; * p ≤ 0.05, *** p ≤ 0.001. Note that fen fibrate significantly inhibits the formation of α-SMA+ stress
fibers in the TGF-β1-treated HBFs i a dose-dependent manner, and concomitantly, has a slight impact
on the total α-SMA level.
2.2. Actin Cytoskel ton Architecture Is Reorganized by Fenofibr te in TGF-β1-Treated HBFs
To mechanically address the inhibition of α-SMA incorporation into stress fibers, we further
concentrated on their actin cytoskeleton architecture in the fenofibrate-treated HBFs. Fenofibrate
considerably reduced the thickness and affected cytoplasmic localization of stress fibers in the
TGF-β1-treated HBFs (Figure 3A).
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Figure 3. Fenofibrate affects actin cytoskeleton architecture. (A) HBFs were cultured in DMEM 
supplemented with TGF-β1 (5 ng/mL) in the absence or presence of FF (1–25 μM) for seven days. Then, 
the cells were fixed with 3.7% formaldehyde, permeabilized, and immunostained for actin (red) and 
DNA (blue). Representative images were selected and presented. Intensity of actin fiber fluorescence 
in sections is presented on plot profiles and quantified in graphs. Scale bar = 25 μm. (B) Cellular 
content of the selected focal adhesion proteins was measured by Western blots and (C) in-cell ELISA. 
Representative images of vinculin-rich focal adhesions are presented, (D) quantified and grouped by 
size. Data represent the mean ± SEM of five independent experiments in all analyses. Statistical 
significances were tested using one-way ANOVA with the Bonferroni multiple comparison post hoc 
test; * p ≤ 0.05; *** p ≤ 0.001. Note that fenofibrate affects the architecture of actin cytoskeletons and 
arrangement of focal adhesion maturation in the TGF-β1-treated HBFs. 
Figure 3. Fenofibrate affects actin cytoskeleton architecture. (A) HBFs were cultured in DMEM
supplemented with TGF-β1 (5 ng/mL) in the absence or presence of FF (1–25 µM) for seven days. Then,
the cells were fixed with 3.7% formaldehyde, permeabilized, and immunostained for actin (red) and
DNA (blue). Representative images were selected and presented. Intensity of actin fiber fluorescence
in sections is presented on plot profiles and quantified in graphs. Scale bar = 25 µm. (B) Cellular
content of the selected focal adhesion proteins was measured by Western blots and (C) in-cell ELISA.
Representative images of vinculin-rich focal adhesions are presented, (D) quantified and grouped
by size. Data represent the mean ± SEM of five independent experiments in all analyses. Statistical
significances were tested using one-way ANOVA with the Bonferroni multiple comparison post hoc
test; * p ≤ 0.05; *** p ≤ 0.001. Note that fenofibrate affects the architecture of actin cytoskeletons and
arrangement of focal adhesion maturation in the TGF-β1-treated HBFs.
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These microscopic observations were confirmed by fluorometric analyses, which revealed fewer
prominent stress fibers in the TGF-β1/fenofibrate-treated HBFs. Accordingly, the visualization
of vinculin-rich focal adhesions (FAs) in these cells by total internal reflection fluorescence (TIRF)
microscopy revealed the reduction in the number of supermature FAs (length > 4 µm) in cells co-treated
with TGF-β1 and fenofibrate (Figure 3B). However, this effect was not associated with the total number
of focal adhesions. However, immunoenzymatic immunoblot analyses and in-cell ELISA showed
rather negligible effects of fenofibrate on the expression of FA proteins (Figure 3C,D). These data
indicate that fenofibrate exerts an inhibitory effect on the TGF-β1-induced incorporation of α-SMA
into stress fibers via an effect on actin cytoskeleton architecture.
2.3. Fenofibrate Inhibits the TGF-β1/Smad Signaling Pathway in TGF-β1-Treated HBFs
The TGF-β1-induced FMT of HBFs is predominantly regulated by the canonical
Smad2/Smad3-dependent signaling pathway [17,23–26]. To elucidate the molecular mechanisms
underlying the inhibitory effect of fenofibrate on the TGF-β1-induced FMT, we followed the fate
of Smad2 and Smad3 in the HBFs that underwent fenofibrate treatment. A significant increase in
the phosphorylated (p)-Smad2 and p-Smad3 levels was observed in HBFs after TGF-β1 treatment
(Figure 4A).
However, Smad2 and Smad3 phosphorylation levels were considerably reduced by fenofibrate in a
time- (Figure 4A) and dose-dependent manner (Figure 4B). This effect was correlated with the reduced
number of p-Smad2+ HBF nuclei observed in the presence of TGF-β1/fenofibrate in comparison to
the TGF-β1 control (from ca. 60% in TGF-β1-treated HBFs to 25–30% in TGF-β1/fenofibrate-treated
HBFs (Figure 4C,D). The discrepancy between the fenofibrate-induced inhibition of TGF-β1/Smad
signaling and FMT efficiency, as well as a relatively weak effect of fenofibrate on α-SMA expression,
prompted us to estimate the involvement of non-canonical signaling pathways in HBF reactions to
fenofibrate. Immunoblotting studies did not reveal any effect of fenofibrate on the TGF-β1-induced
activation of Akt (also known as protein kinase B or PKB) and p38 mitogen-activated protein kinase
(also called Cytokinin Specific Binding Protein or CSBP), indicating that neither pathways is involved
in the observed phenomena (data not shown). Cyclic changes in extracellular signal–regulated
kinases (ERK)1/2 phosphorylation status observed in HBFs upon TGF-β1 treatment were not affected
by fenofibrate (Figure 4E). ERK1/2 signaling is involved in α-SMA regulation [27,28]. Therefore,
these data explain the lack of significant inhibition of the α-SMA levels that accompanies the
fenofibrate-induced inhibition of TGF-β1/Smad signaling and of α-SMA incorporation into stress
fibers in fenofibrate-treated HBF populations.
2.4. Connexin 43 Is Involved in Fenofibrate-Induced Attenuation of the FMT in TGF-β1-Treated HBFs
In our recent report, we presented the key role of connexin 43 (Cx43), a protein that constitutes
gap junctional channels between HBFs, in the regulation of the TGF-β1-induced FMT in HBF
populations [23]. In accordance with these data, immunoenzymatic in-cell ELISA and Western blot
analyses showed significantly increased Cx43 levels in the TGF-β1-treated HBFs, characterized by the
highest sensitivity to TGF-β1/fenofibrate. Prompted by the attenuation of TGF-β1/Smad signaling and
the decrease in α-SMA+ stress fiber formation in the fenofibrate-treated HBFs, we also examined the
effect of fenofibrate on Cx43 levels in HBF populations. The combined TGF-β1/fenofibrate treatment
attenuated Cx43 levels in comparison to the TGF-β1-treated cells (Figure 5A,B).
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Figure 4. Fenofibrate affects TGF-β1-dependent Smad signaling pathway activity in HBFs. (A) Cells 
cultivated in DMEM supplemented with TGF-β1 (5 ng/ml) in the absence or presence of FF (10 μM) 
for different time points (0–120 minutes). Then, the cells were lysed, and the total cell lysates were 
analyzed using immunoblotting. Smad2, Smad3, and their phosphorylated forms were detected using 
primary antibodies against Smad2, Smad3, phosphorylated (p)-Smad2(Ser465/467) and p-
Smad3(Ser423/425), respectively (see Materials and methods; Section 4.7). Representative membranes 
are shown. Densitometric quantification is presented as values of relative optical densities (ROD) (n 
= 5) of phospho-Smads in relation to Smads (as control proteins). (B) Immunoblots with relative 
optical density (ROD) of p-Smad2(Ser467) in relation to Smad2 are presented in HBFs treated by TGF-
β1 (5ng/ml) in the absence or presence of FF (1–25 μM) for 1 h. The results represent mean ± SEM of 
five independent experiments. (C,D) HBFs (n = 10) cultured in the conditions described in (B) were 
fixed with 3.7% formaldehyde/PBS, permeabilized, and immunostained for p-Smad2. The fractions 
i r . fi r t ff t - 1-dependent S ad si aling at ay cti it i . ( ) ll
lti t i l t it - ( L) in the absence or presence of FF (10 µ )
t ti e points (0–120 min). Then, the cells were lysed, and the total cell lysates were analyzed
using immu oblotting. Smad2, Smad3, and their phosphorylated forms were detected using primary
antibodies against Smad2, Smad3, phosphorylated (p)-Smad2(Ser465/467) nd p-Smad3(Ser423/425),
respectively (see Materials and methods; Section 4.7). Representative m mbr nes are shown.
D nsitometric quantification is presented as values of re ative optical densities (ROD) (n = 5 of
phospho-Smads in relat on to Smads (as control pro eins). (B) Immunoblots with relative optical
density (ROD) of p-Smad2(Ser467) in relation to Smad2 re p sented in HBFs treat d by TGF-β1
(5 ng/mL) in the absence or presence of FF (1–25 µM) for 1 h. The results represent ean
fi t i ts. ( , ) s ( 10) c lt re i t iti s ri e i )
fi . PBS, per eabilized, and i ostained f r .
of cells with pSmad2+ nuclei were determined using fluorescence microscopy. Representative photos
were selected. Scale bar = 25 µm. Data represent the mean ± SEM of ten independent experiments in
triplicate. (E) HBFs cultured in the conditions described in (A) were lysed and analyzed by Western
blot. Representative immunoblots with relative optical density of p-ERK1/2 in relation to ERK1/2 are
presented. Statistical significances were tested using one-way ANOVA with the Bonferroni multiple
comparison post hoc Test; * p ≤ 0.05. Note that fenofibrate efficiently attenuates the TGF-β1-induced
Smad signaling, but not the ERK-dependent pathway.
This phenomenon was confirmed by immunofluorescence studies and with cytofluorimetric
analyses of HBFs (Figure 5C,D). These results clearly show the inhibitory effect of fenofibrate on
Cx43 levels in the TGF-β1-treated bronchial fibroblasts, which corresponds to the attenuation of the
TGF-β1/Smad2/3 signaling pathway and FMT efficiency.
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Figure 5. Connexin 43 (Cx43) levels are reduced in TGF-β1-treated HBFs in response to fenofibrate 
administration. (A) HBFs were cultured in DMEM supplemented with TGF-β1 (5 ng/mL) in the 
absence or presence of FF (25 μM) for seven days. Cellular content of Cx43 was measured by in-cell 
ELISA and (B) Western blot analyses of total cellular lysates. Representative immunoblots are 
presented; bar graphs show the relative optical density of densitometrically quantified Cx43 protein 
levels in relation to GAPDH as a housekeeping protein. (C) HBFs were cultured in DMEM 
supplemented with TGF-β1 (5 ng/mL) in the presence or absence of FF (25 μM) for seven days and 
immunostained for Cx43 (red) and DNA (blue). Representative images are presented. Scale bar = 25 
μm. (D) Levels of Cx43 were identified using fluorimetry analyses and presented in relation to the 
control signal of DNA. Data represent the mean ± SEM of five independent experiments in all 
analyses. Statistical significances were tested using one-way ANOVA with the Bonferroni multiple 
comparison post hoc test; * p ≤ 0.05. Note that fenofibrate significantly reduces the level of Cx43 in 
TGF-β1-treated HBFs. 
3. Discussion 
The majority of drugs currently available for bronchial asthma therapy do not significantly 
inhibit the fibrotic changes in the bronchial wall [29]. Only a few anti-inflammatory drugs used in the 
treatment of asthma (e.g., β2-adrenergic receptor agonists, glucocorticosteroids [29], methylxanthines 
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and hows, for the first tim , that fenofibrate can efficiently interfere w th the TGF-β1-induced
myofibroblastic differenti ion of bron hial fibroblasts derived from asthmatic patients.
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Despite intensive research on bronchial remodeling in asthma, the mechanisms involved in
the TGF-β1-induced FMT (the key event of subepithelial fibrosis in the asthmatic bronchial wall)
are only partially understood. Heritable predilection of asthmatic HBFs may participate in this
process. We recently showed that HBFs derived from asthmatic patients display a considerably
higher susceptibility to TGF-β1–induced myofibroblastic differentiation than their non-asthmatic
counterparts [14,23,36]. The induction of the FMT in HBF populations by the addition of exogenous
TGF-β1 mimics the in vivo asthmatic process triggered by local secretion of TGF-β1 within the
inflammatory milieu. TGF-β1 is one of the most important pro-fibrotic cytokines in vivo, and its
expression increases in asthmatic airways [37]. Therefore, the experimental model, based on primary
HBFs expanded directly from bronchial biopsies of different patients with diagnosed asthma (n = 10),
is suitable for the analyses of the FMT background, as well as for pharmacokinetic studies. This model
efficiently imitates the conditions and microenvironmental properties of asthmatic bronchial tissue.
Using this model, we previously demonstrated that lovastatin and zaragozic acid A (inhibitors of the
cholesterol synthesis pathway) reduce the efficiency of the TGF-β1-induced FMT in asthmatic HBF
populations by lowering intracellular cholesterol levels [17]. Here, we show the inhibitory effect of
fenofibrate on the TGF-β1-induced phenotypical transitions of HBFs. Notably, the inhibitory effects
were reported in the presence of 10–25 µM fenofibrate, i.e., concentrations found in the sera of patients
receiving therapeutic doses of fenofibrate [38–40]. Next, these effects were found in the absence
of any visible cytotoxic effects [41,42]. This is an important finding, as HBF apoptosis or necrosis
might result in improper responses of the immune system, leading to secondary inflammation [3].
Thus, dose-dependent inhibition of the TGF-β1-induced FMT in asthmatic HBF populations places
this agent among many remarkable candidates for anti-fibrotic therapy in asthma.
Mechanistic studies demonstrated that fenofibrate attenuates the TGF-β1-induced FMT via the
inhibition of the canonical Smad signaling pathway. This outcome is illustrated by significantly
decreased Smad2/Smad3 phosphorylation levels and their attenuated nuclear translocation.
Fenofibrate was already shown to inhibit the TGF-β1/Smad signaling axis in fibrotic processes
in a model of diabetic nephropathy [43]. Previously, we showed the impact of statins [17] and
methylxanthines [30] on the attenuation of the TGF-β1/Smad2 signaling axis in HBFs derived
from asthma patients. Therefore, a fenofibrate-induced impairment of this signaling pathway may
be associated with fenofibrate interference with cholesterol metabolism [31,44–46]. The possible
mechanisms of this dependence may be based on its interference with the structure of membrane
lipid rafts. These cholesterol-rich domains are disintegrated in response to cholesterol depletion,
which conceivably can affect TGF-β1-dependent signaling [17,47]. However, fenofibrate displays
pleiotropic activity; therefore, it can also affect the FMT of asthmatic HBFs in a manner independent of
its lipid-lowering activity.
Furthermore, the upregulation of Cx43 levels observed in HBFs upon treatment of TGF-β1 was
significantly and dose-dependently reduced by fenofibrate. Cx43 regulates cellular processes in
two different ways: gap junctional intercellular coupling (GJIC)-dependent and GJIC-independent
methods [48–50]. We previously showed GJIC-independent associations between TGF-β1/Smad2
signaling and TGF-β1-induced FMT and Cx43 function in HBFs [23]. The involvement of
Cx43 in myofibroblast formation was also demonstrated in cardiac tissue [51]. These data
indicate that fenofibrate interferes with TGF-β1/Smad2 signaling upstream of Cx43 involvement,
which indirectly confirms the involvement of raft-dependent mechanism(s). However, we did not
observe any considerable reduction in α-SMA+ upregulation in the TGF-β1/fenofibrate-treated HBFs.
This apparent discrepancy can only be explained in terms of activation of fenofibrate-resistant signaling
by TGF-β1 or by the involvement of other signaling pathways, leading to a pro-fibrotic response of
these cells. Indeed, ERK1/2-dependent signaling, which was recently shown to participate in α-SMA+
regulation [23,28], is not attenuated by fenofibrate.
Rather than via the inhibition of α-SMA levels, fenofibrate may attenuate myofibroblast formation
in HBF populations via inhibition of the α-SMA incorporation into stress fibers. Indeed, the impairment
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of the Smad2/3 signaling pathway was correlated with the inhibition of α-SMA+ incorporation
into stress fibers. We previously showed that the Cx43-mediated GJIC regulates the formation of
the α-SMA+ stress fibers. These mechanisms sustain α-SMA+ upregulation in the TGF-β1-treated
HBFs; however, they do not allow for the integration of α-SMA+ into stress fibers. Chemical
inhibition of GJIC does not affect the Cx43 and α-SMA levels, but significantly reduces the percentage
of myofibroblasts [23]. Since fenofibrate-induced Cx43 downregulation inevitably impairs GJIC,
we postulate the involvement of GJIC in this phenomenon. It is unclear whether the impairment
of the α-SMA+ incorporation into stress fibers is the cause or effect of cytoskeletal rearrangements.
However, similar rearrangements in the architecture of the actin cytoskeleton were demonstrated in
fenofibrate-treated endothelial cells [42], which indicates the fenofibrate-specific nature of this effect.
It is, thus, unambiguous that fenofibrate can prevent the excessive contractile activity of myofibroblasts
in the asthmatic bronchial wall.
In summary, for the first time, we showed that fenofibrate directly affects the TGF-β1-induced
FMT of human bronchial fibroblasts in vitro via the attenuation of the TGF-β1/Smad2/3 axis and a
concomitant block of α-SMA incorporation into stress fibers via connexin 43 function. Because the
FMT is crucial for the asthmatic process, the application of fenofibrate should potentially be considered
in the chemoprevention of subepithelial fibrosis in asthma. A clinical and therapeutic potential of
fenofibrate may also be expanded for the future development of new viable therapeutic approaches
for asthma medication.
4. Materials and Methods
4.1. HBF In Vitro Cultures
The primary human bronchial fibroblasts (HBFs) were established as described previously [52]
from bronchial biopsy explants derived from 10 patients with asthma severity 3–4 (Global Initiative
for Asthma (GINA) classification). Briefly, all individuals were treated in the Department of Medicine
of the Jagiellonian University Medical College and remained in stable clinical conditions. The study
group consisted of five females and five males aged 36.7 ± 11.1 years. The patients were characterized
by the reduced value of the forced expiratory volume in one second (the average FEV1%: 67.3 ± 22.5).
The mean duration of asthma in the experimental group was 9.9 ± 6.1 years. The study was approved
by the Jagiellonian University Ethics Committee (Decision No. 122.6120.16.2016; 28 January 2016) and
all the patients provided informed consent to participate. Phenotypes of the established primary HBF
cultures were verified by immunofluorescence staining of α-smooth muscle actin (α-SMA), vimentin,
and desmin [53]. All cells expressed vimentin-positive staining, whereas the expression of desmin was
not observed. In the HBF populations, α-SMA-positive staining (α-SMA+) was observed in ca. 5% of
cells. HBFs were cultured in a complete medium (Dulbecco’s modified Eagle medium; Sigma-Aldrich,
St. Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS; GibcoTM, Thermo Fisher
Scientific, Waltham, MA, USA), and a penicillin/streptomycin cocktail (P4333; Sigma-Aldrich, St. Louis,
MO, USA) as described previously [23,30]. For each experiment (unless otherwise noted), the cells were
seeded at a density of 5000 cells/cm2 and cultured in complete medium for 24 h, followed by 24 h in
serum-free medium containing 0.1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO, USA).
When indicated, human recombinant TGF-β1 (5 ng/mL, BD Bioscience) and/or fenofibrate (1–50 µM,
stock: 8 mM in dimethyl sulfoxide (DMSO); Sigma-Aldrich, St. Louis, MO, USA) were administered.
4.2. Viability and Proliferation Tests
Cell viability was determined after one, two, and seven days of incubation with fenofibrate
(1–50 µM) by the fluorescein diacetate (FDA)/ethidium bromide (EtBr) test [17] using a Leica DM IRE2
microscope, and the results are expressed as the percentage of the FDA+/ EtBr− cells.
For the proliferation tests, the cells were cultured in complete medium for 24 h and then in
a serum-free medium with or without fenofibrate (0–50 µM) for varied times, from one to seven
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days. Then, the cells were fixed with 3.7% formaldehyde/PBS, and the crystal violet assay was
performed [30]. The results are shown as absorbance values (540 nm).
4.3. Movement of Individual Cells—Time-Lapse Monitoring
The cells were seeded into 12-well plates. After that, fenofibrate (25 µM) was added for 48 h
to the proper wells. Time-lapse imaging was performed with a fully motorized Leica DMI6000B
microscope equipped with a monochrome digital DFC360FX CCD camera (all by Leica Microsystems,
Wetzlar, Germany). A temperature of 37 ◦C and a 5% CO2 concentration were maintained with an
environmental control system. Images were captured with integrated modulation contrast (IMC) every
15 min for 13 h. The obtained image series was analyzed manually with the Hiro 1.0.0.4 software.
Trajectories for 50 individual cell centroids were constructed and presented as circular diagrams,
with the starting points situated at the plot center. The parameters describing the motility of the
cells, the average speed of cell movement (ASCM; µm/h), and the average rate of cell displacement
(ARCD; µm/h), were calculated as described elsewhere [41,54,55].
4.4. Cholesterol Content Assay
For the experiments, the cells were grown in complete medium for seven days (at a density
of 3250 cells/cm2). Isolation of intracellular cholesterol was carried out in duplicate using a
750-µL hexane/isopropanol mixture (3:2) per well for 30 min with shaking. The supernatants were
collected in glass bottles and evaporated under a gentle stream of nitrogen. Cholesterol levels were
determined with the use of an AmplexTM Red Cholesterol Assay Kit (InvitrogenTM, Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s protocol, and measured using an
Infinite M200PRO microplate reader (Tecan; excitation of fluorescence: 540 nm; emission: 590 nm).
The results were converted relative to the cholesterol curve and are shown as the concentration of
cholesterol (µg/mL).
4.5. Immunofluorescence Staining
For the immunocytofluorescence analyses, HBFs were cultured in 24-well plates (µPlate
24 well; ibidi) in control or experimental conditions for a varied period (1 h for p-Smad2;
seven days for α-SMA, Cx43, and vinculin analyses). Afterward, the cells were fixed with
3.7% formaldehyde/PBS, permeabilized with 0.1% Triton X-100/PBS, blocked with 1% BSA/PBS
(Sigma-Aldrich), and incubated with primary antibodies: mouse monoclonal IgG against α-SMA
(A2547, clone 1A4, 1:400); rabbit polyclonal IgG against connexin 43 (C6219, 1:200), rabbit polyclonal
IgG against p(Ser467)-Smad2 (SAB4300251, 1:100), rabbit polyclonal IgG against Smad2 (SAB4501808,
1:100), and mouse monoclonal IgG against vinculin (V9131, 1:1000), all from Sigma-Aldrich, St. Louis,
MO, USA, and appropriate secondary antibodies were applied: AlexaFluor488-conjugated goat
anti-mouse IgG and AlexaFluor546-conjugated goat anti-rabbit IgG (all: 1:500, Life Technologies,
Thermo Fisher Scientific, Waltham, MA, USA). Some were counterstained with Hoechst 33342
(1 µg/mL, Sigma-Aldrich, St. Louis, MO, USA) and phalloidin conjugated with AlexaFluor546
(Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA). Images were acquired using a
Leica DMI6000B inverted microscope (Leica Microsystems, Wetzlar, Germany) equipped with the
LAS-X software for image processing. The FMT efficiency was counted as the percentage of cells
with α-SMA-positive microfilaments in the HBF populations. Similarly, activity of the Smad signaling
pathway was determined by the percentage of cells expressing a strong signal in the nuclear area
from p-Smad2 staining. Quantitative analysis of actin cytoskeletons was performed with Fiji ImageJ
software, version 1.51s [56]. Plot profiles perpendicular to bundles of stress fibers were created, and the
signal for particular spikes was analyzed. The averaged signal for at least 50 stress fibers was compared
between the conditions. Cytofluorimetric analyses of Cx43 levels were performed using the same
excitation/exposure settings as described previously [23,57].
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4.6. Focal Adhesion Imaging
Visualization of focal adhesions (FAs) was conducted with the same fluorescence microscope,
equipped with a high-numerical aperture objective of 100× magnification and total internal reflection
fluorescence (TIRF) module. TIRF microscopy was used to selectively visualize vinculin near the
plasma membrane. To obtain quantitative data, HBFs were transfected with Lipofectamine 2000
transfection reagent and mEmerald-Vinculin-23 plasmid, which was a gift from Michael Davidson
(Addgene plasmid #54302). Then, 24 h after transfection, the cells were incubated with TGF-β1 and
visualized five days later. Captured images were analyzed automatically with the Fiji ImageJ software,
version 1.51s, and a macro based on the algorithm published previously [58] with minor modifications.
The analysis provided data about the area and length of particular focal contacts. The results are
presented as a fraction of the overall FA area covered by FAs of particular types.
4.7. Protein Extraction and Western Blotting
HBF cultures were lysed as described previously [23,30], and the protein content in the supernatant
was determined using the Bradford method. Protein samples (30 µg/lane) were electrophoresed on 10%
SDS-polyacrylamide gels and transferred to polyvinylidene difluoride (PVDF) membranes (Bio Rad,
Hercules, CA, USA) as described previously [23,57]. Next, after blocking, the membranes were
incubated overnight at 4 ◦C with primary antibodies: rabbit polyclonal IgG against p(Ser467)-Smad2
(1:500), rabbit polyclonal IgG against Cx43 (1:2000), mouse monoclonal IgG against α-SMA (1:2000),
mouse monoclonal IgG against vinculin (1:1000), mouse monoclonal IgG against β-tubulin (1:1000),
and mouse monoclonal IgG against glyceraldehyde-3-phosphate dehydrogenase GAPDH (1:3000),
all from Sigma-Aldrich, St. Louis, MO, USA; rabbit monoclonal IgG against Smad2 (D43B4), rabbit
monoclonal IgG against p(Ser465/467)-Smad2 (138D4), rabbit monoclonal IgG against Smad3 (C67H9),
rabbit monoclonal IgG against p(Ser423/425)-Smad3 (C25A9), rabbit polyclonal IgG against Focal
adhesion kinase (FAK), rabbit polyclonal IgG against p(Thr202/Tyr204)-Erk1/2, and rabbit polyclonal
IgG against Erk1/2 (all: 1:500; Cell Signaling Technology® Danvers, MA, USA).
After triple-washing with TBST (10 mM Tris–HCl, 150 mM NaCl, 0.05% Tween-20), horseradish
peroxidase (HRP)-conjugated anti-mouse or anti-rabbit IgG (all: 1:3000; Life Technologies) diluted
in 2.5% skim milk/TBST were added for 1 h. For band detection, Luminata Crescendo Western
HRP Substrate (Merck Millipore, Burlington, MA, USA) and a chemiluminescence imaging system
(MicroChemi; DNR Bio-Imaging Systems, Jerusalem, Israel) were used. Band intensities were
quantified using the Fiji ImageJ software, version 1.51s.
4.8. Measurement of Protein Levels Using In-Cell ELISA
The cells were seeded into 96-well plates and treated with a fresh serum-free medium containing
recombinant TGF-β1 (5 ng/mL) alone or in combination with fenofibrate (1, 10, or 25 µM) for
seven days. The in-cell ELISA protocol [30] was performed using antibodies from a Focal Adhesion
Protein Antibody Sampler Kit (13430T; Cell Signaling Technology®), rabbit polyclonal anti-fibronectin
(Sigma-Aldrich, St. Louis, MO, USA), or those against α-SMA and Cx43 (1:2000 in 1% BSA/PBS,
Sigma-Aldrich, St. Louis, MO, USA). The results are shown as the absorbance value (450 nm; Microplate
Reader, Thermo Scientific, Multiskan FC) corresponding to the relative amount of protein level.
4.9. Statistics
Data are presented as the mean ± standard error of the mean (SEM) from at least three
independent experiments. Comparisons between groups were performed by one-way or two-way
analysis of variance (ANOVA) followed by the post hoc Bonferroni multiple comparison test.
Differences were considered statistically significant at a p-value < 0.05 (*) or <0.001 (***).
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